Jazz Pharmaceuticals' unrestricted cash, cash equivalents and marketable securities balance as of September 30, 2007 was $130.9 million. During the quarter ended September 30, 2007, net cash used in operating activities was $15.4 million.
"As our commercial organization ramps up for the anticipated commercial launch of Luvox CR in early 2008, we have also made progress in all four of our most advanced clinical development programs during the past few months," said Samuel R. Saks, M.D., Chief Executive Officer. "We continue to make important progress on our development programs for the treatment of fibromyalgia, recurrent acute repetitive seizures, restless legs syndrome and partial epilepsy."
-- Expansion of Jazz Pharmaceuticals' specialty sales force in preparation
for the commercial launch of Luvox CR began in August 2007, with more
than 100 new field sales management and specialty sales consultants
hired as of October 31, 2007. The PDUFA action date for Luvox CR is
December 22, 2007. The company expects to commence promotion of Luvox
CR in the United States during the first quarter of 2008, subject to
approval by the U.S. Food and Drug Administration (FDA).
-- In August 2007, a clinical enrollment milestone was achieved in the
Phase III development program for fibromyalgia syndrome, JZP-6,
triggering a $7.5 million payment to Jazz Pharmaceuticals under the
company's development agreement with UCB Pharma Limited. The payment
was recognized as contract revenue in the third quarter of 2007.
-- In September 2007, Jazz Pharmaceuticals submitted an Investigational
New Drug application to the FDA for JZP-8, a product candidate for the
treatment of recurrent acute repetitive seizures. The FDA has<
|SOURCE Jazz Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved